Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Genomics Innovation PCLBKK:BKGI +1.51%45 PB Ratio is 2.20 as of Jul. 31, 2026, which is 1% above its 10-year median of 2.17. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks worse than 52.58% on this metric.
Bangkok Genomics Innovation PCL stock PB Ratio (=2.2) is close to 1-year high of 2.31.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's PB Ratio or its related term are showing as below:
BKK:BKGI'
s PB Ratio Range Over the Past 10 Years
Min: 1.35 Med: 2.17 Max: 13.87
Current: 2.2
During the past 7 years, Bangkok Genomics Innovation PCL's highest PB Ratio was 13.87. The lowest was 1.35. And the median was 2.17.
BKK:BKGI's PB Ratio is ranked worse than 52.58% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.025
vs BKK:BKGI: 2.20
During the past 12 months, Bangkok Genomics Innovation PCL's average Book Value Per Share Growth Rate was 2.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 30.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 60.00% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Bangkok Genomics Innovation PCL was 98.30% per year. The lowest was 30.60% per year. And the median was 64.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bangkok Genomics Innovation PCL PB Ratio Related Terms
Bangkok Genomics Innovation PCL PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's PB Ratio falls into.
Bangkok Genomics Innovation PCL PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a PB Ratio of 2.20 as of Jul. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is near median its historical median of 2.17. Over the past decade, Bangkok Genomics Innovation PCL's PB Ratio has ranged from 1.35 to 13.87. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #102 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 52.6%.
Is Bangkok Genomics Innovation PCL's PB Ratio too high?
Bangkok Genomics Innovation PCL's current PB Ratio of 2.20 is near median its 10-year median of 2.17. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 13.87. The Medical Diagnostics & Research industry median PB Ratio is 2.03. Bangkok Genomics Innovation PCL's value of 2.20 is 8.6% above this industry median. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #102 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #102 out of 194 companies for PB Ratio. This places Bangkok Genomics Innovation PCL in the lower half of its industry. The industry median PB Ratio is 2.03. Bangkok Genomics Innovation PCL's value of 2.20 is 8.6% above this benchmark. Historically, Bangkok Genomics Innovation PCL's own PB Ratio has ranged from 1.35 to 13.87 over the past decade. While the company's 10-year median is 2.17 vs. the industry median of 2.03, Bangkok Genomics Innovation PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.03, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Genomics Innovation PCL's current PB Ratio of 2.20 is 8.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bangkok Genomics Innovation PCL and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current PB Ratio is 2.20, which is near median its own 10-year median of 2.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current PB Ratio of 2.20. The current PB Ratio is 2.20, which is near median its 10-year median of 2.17 and 8.6% above the Medical Diagnostics & Research industry median of 2.03. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current PB Ratio is 2.20 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
